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Introduction: L'efficacité des inhibiteurs de l'enzyme de conversion de !'angiotensine (ACEI) 
dans le traitement de l'hypertension artérielle chez les patients africains est controversée. 
Objectif: Nous avons examiné la baisse de la tension artérielle ambulatoire (ABP) en réponse 
à un diurétique et un ACEI chez des patients hype1iendus d'origine africaine et nous avons 
évalué les différentes caractéristiques déterminant l'efficacité du traitement. 
Méthodes: Etude en simple-aveugle randomisée, en crossover AB/BA. Arrangement: 
Familles hypertendues d'origine africaine de la population générale des Seychelles. 
Participants : 52 patients (29 hommes et 23 femmes) sur 62 patients hypertendus éligibles ont 
été inclus. Le principal résultat était la mesure de la réponse del' ABP à 20 mg de lisinopril 
(LIS) ou 25 mg d'hydrochlorothiazide (HCT) quotidiennement pendant quatre semaines. 
Résultats: Le jour, la réponse systolique/diastolique del' ABP sous HCT était de 4.9 (95% 
intervalle de confiance (IC) 1.2-8.6)/3.6 (1.0-6.2) mm Hg pour les hommes et 12.9 (9.2-
16.6)/6.3 (3.7-8.8) mm Hg pour les femmes. Sous LIS, la réponse était de 18.8 (15.0-
22.5)/14.6 (12.0-17.1) mm Hg pour les hommes et de 12.4 (8.7-16.2)/7.7 (5.1-10.2) mm Hg 
pour les femmes. La nuit, la réponse systolique/diastolique sous HCT était de 5.0 (0.6-9.4)/2.7 
((-0.4)-5.7) mm Hg pour les hommes et de 11.5 (7.1-16.0)/5.7 (2.6-8.8) mm Hg pour les 
femmes, et sous LIS était de 18.7 (14.2-22.1)/15.4 (12.4-18.5) mm Hg pour les hommes et de 
3.5 ((-1.0)-7.9)/2.3 ((-0.8)-5.4) mm Hg pour les femmes. L'analyse de régression linéaire 
multiple a montré que le sexe est un prédicteur indépendant de la réponse tensionnelle à 
l'HCT et au LIS. 
Conclusions : Les patients hypertendus d'origine africaine ont présenté une baisse 
tensionnelle plus grande en réponse au LIS qu'à l'HCT. Les hommes ont mieux répondu au 
LIS qu'à l'HCT alors que les femmes ont répondu de manière similaire aux deux traitements. 
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Gender difference in the response to an angiotensin .. 
converting enzyme inhibitor and a diuretic in hypertensive 
patients of African descent 
Catherine Falconneta,b, Murielle Bochudb,c, Pascal Bovetb,c, Marc Maillarda 
and Michel Burniera 
Background The efticacy of angiotensin-converting 
enzyme (ACE) inhibitors in decreasing blood pressure in 
African patients is controversial. 
Objective We examined the ambulatory blood pressure 
(ABP) response to a diuretic and an ACE inhibitor in 
hypertensive patients of East African descent and 
evaluated the individual characteristics that determined 
treatment efticacy. 
Design A single-blind randomized AB/BA crossover 
design. 
Setting Hypertensive families of East African descent from 
the general population in the Seychelles. 
Participants Fifty-two (29 men and 23 women) out of 62 
eligible hypertensive patients were included. 
Main outcome measures ABP response to 20 mg 
lisinopril (LIS) daily and 25 mg hydrochlorothiazide (HCT) 
daily given for a 4-week period. 
Results The daytime systolic/diastolic ABP response to 
HCT was 4.9 [95% confidence interval (Cl) 1.2-8.6]/3.6 
(1.0-6.2) mmHg for men and 12.9 (9.2-16.6)/6.3 (3.7-
8.8) mmHg for women. With LIS the response was 18.8 
(15.0-22.5)/14.6 (12.0-17.1) mmHg for men and 12.4 
(8.7-16.2)/7.7 (5.1-10.2) mmHg for women. The night-
Introduction 
It bas been reported that blood pressure is lowered less 
with angiotensin-converting enzyme (ACE) inhibitors 
than with diuretics in individuals of African descent 
[1-4]. I-Iowever, situations that stimulate the renin-
angiotensin system, such as taking a diuretic or having 
a low dietary sait intake, can restore a good response to 
blockade of the rcnin-angiotensin system in African-
Americans [3,5] and in Africans [6-8]. Likewise, main-
taining a low sait intake can diminish the race-related 
difference in drug response [9]. 
In this study we examined the ambulatory blood 
pressure (ABP) responses to a diuretic and to an ACE 
inhibitor in hypertensive patients of African descent 
using a randornized single-blind crossover design. In 
0263-6352 © 2004 Lippincott Williams & Wilkins 
time systolic/diastolic response to HCT was 5.0 (0.6-9.4)/ 
2.7 [(-0.4)-5.7] mmHg for men and 11.5 (7.1-16.0)/5.7 
(2.6-8.8) mmHg for women, and to LIS was 18.7 (14.2-
22.1 )/15.4 (12.4-18.5) mmHg for men and 3.5 [(-1.0)-
7.9]/2.3 [(-0.8)-5.4] mmHg for women. Linear regression 
analyses showed that gender is an independent predictor 
of the ABP responses to HCT and to LIS. 
Conclusions Hypertensive patients of African descent 
responded better to LIS than to HCT. Men responded 
better to LIS than to HCT and women responded similarly 
to both drugs. J Hypertens 22:1213-1220 © 2004 
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view of the known variability in the individual response 
to antihypertensive drugs [ 10-13], we also examined 
individual characteristics that deterrnine treatment effi-
cacy. 
Methods and subjects 
The study took place in the Seychelles islands, which 
are populated prcclominantly by individuals of East 
African descent. Tvvo previous population surveys 
showed a high prevalence of hypertension in the adult 
population [14,15]. 
Participants in this study were recruited from a family-
based stucly of genetic determinants of hypertension 
conclucted between August 1999 and January 2002. For 
this genetic study, families with several hypertensive 
DOi: 10. 1097/01.hjh.0000125416.50839.aO 
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patients 'Nere selected on the basis of a national hyper-
tension register. Participants in this study vvere indivi-
duals who had a claytime ABP > 140/90 mmHg after a 
2-week washout periocl during which antihypertensive 
medications, if any, were stopped. Patients vvere ex-
clucled if they presented a contraindication to one of 
the stucly drugs (e.g. gout, known previous allergie 
reaction), systolic/diastolic blood pressure > 200/ 
120 mmHg, renal failure, insulin-dependent diabetes 
mellitus or a history of cardiovascular event during the 
previous 6 months. Pre-menopausal women were in-
cludecl only if they had unclergone sterilization or were 
taking a contraceptive treatment. After the 2-week 
washout period and prior to starting the drug treat-
ments, participants were requested to collect urine 
during 24 h under their usual cliet. The study vvas 
approved by the Ministry of Health of Seychelles and 
the ethical committee of the University of Lausanne 
(Switzerland). Ail participants were informed of the 
nature of the study and gave a written informecl 
consent. 
A single-blincl AB/BA crossover design was used. After 
the washout period, the participants were randomly 
allocated, using a block randomization scheme by 
group, to receive a 4-week course of hydrochlorothia-
zide (HCT) (25 mg once daily) followed by another 2-
week washout and a 4-week course of lisinopril (LIS) 
(20 mg once daily) for Group 1 or the inverse sequence 
for Group 2. 
ABP monitoring was performed at the srart and at the 
end of each treatment period (on the day preceding the 
initiation of the medication and on the day preceding 
the cessation of the medication). This investigation was 
conclucted using Diasys devices (DIASYS Integra; 
Novacor SA, Rueil-Malmaison, France) placed on the 
left arm with an appropriately sized cuff. Measurements 
were based on the auscultatory mode relayed by the 
oscillometric mode in case of failure of the auscultatory 
mode. Blood pressure was recorded every 20 min 
during the day and every 30 min during the night. 
Daytime ABP in this study is the average of ail 
validated BP readings benveen 0700 h and patients' 
self-reported bedtime (which ranged between 1930 and 
0100 h, median: 2200 h). Night-time ABP is the average 
of ail validated BP readings between the patients' self-
reported bedtime and 0700 h the next morning. We 
excluded observations for the following reasons: systolic 
blood pressure (SBP) < 50 mmHg or > 250 mmHg; 
diastolic blood pressure (DBP) < 30 mmHg or > 150 
mmHg; differential blood pressure (SBP-DBP) < 10 
mmHg or > 150 mmHg; and pulse < 35 beats/min or 
> 250 beats/min. Ali participants had at least 29 valid 
measurements and 90% at least 40 for each ABP 
monitoring. The average (±SE) number of valid meas-
urements was 37 (± 1) for daytime and 15 (± 1) for 
night-time ABP for HCT, and 38 (± 1) and 15 (± 1), 
respectively, for LIS. 
A subgroup of participants (ll = 33 ), allocated according 
to device availability (1() devices were available), re-
ceived their pills in elcctronic medication bottles 
(meclication event monitoring systems, l'vIE.tvlS; Aardex, 
Zug, Switzerland). Electronic monitoring is considered 
to be the best available approacl1 to monitoring com-
pliance and has been used in several studies [16, 17], 
including one in the Seychelles [18]. Good compliance 
was arbitrarily defined as having more than 90% of days 
with at least one opening of the bottle. There was no 
difference in gender, age, treatment group and initial 
blood pressure between participants who received a 
MEl'vIS device and those who clid not. 
Statistical analysis 
We needed 32 participants to detect a difference of 
5 mmHg (with a standard cleviation of 10 mml-Ig) be-
tween the two treatments with an 80% power and a 5% 
type 1 error. The response to treatment was estimated 
by the difference in systolic/diastolic/mean ABP be-
tween the start (baseline) and the end of the 4-week 
treatment periods. The mean arterial blood pressure 
(MAP) was calculated as 2/3 of the diastolic + 1/3 of the 
systolic blood pressure. Descriptive statistics were con-
clucted using two-sample /-tests for continuous v;lriables 
and chi-square tests for categorical variables. To assess 
the different treatment contrasts, we conducted re-
peatccl measurcs ANOVA, followed by /-tests whenevcr 
the global ANOVA F test was significant. We uscd a 
Bonferroni procedure to account for multiple compari-
sons. Among the contrasts evaluated, we compared 
baseline blood pressure values between groups to assess 
any carry-over effect. The relationship between the 
MAP response (used as the depenclent variable under 
either LIS or HCT) and selected factors [i.e. age, 
gender, body mass index (BMI) and urinary sodium 
excretion] was examined with univariate and multi-
variate linear regression analyses, which included an 
assessment of interaction terms. vVe checked for any 
violation of the assumptions underlying linear regres-
sion. Gender-specific and age-adjusted ABP responses 
were also calculated using linear regression. Analyses 
were clone using Stata 7.0 (Stata Corporation, College 
Station, Texas, USA). Corrected P values < 0.05 were 
consiclered statistically significant. 
Results 
Sixty-one of the 62 eligible patients agreed to part1c1-
pate. Among the 61 participants, 57 completed the 
study (93.4%) and four dropped out [three refused to 
continue and one had side-effects (dizziness while 
under HCT treatment)], and, of these 57, five had 
missing values for night ABP, leaving 52 individuals for 
analysis (Fig. 1 ). Baseline participants' characteristics 
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arc shown in Table 1. Ivicn bac! highcr bascline 
cliastolic ABP pressure than women. Baseline claytime 
and night-time ABP die! not diffcr between groups 
(HCT-LIS sequence versus LIS-HCT sequence). 
The mean (±SE) 24-h urinary sodium excretion bcfore 
treatment was 99 ± 10 mmol/24 h for men and 108 ± 
13 mmol/24 h for women or, cquivalcntly, rcspectively 
5.4 ± 0.6 and 5.9 ± 0.7 g of sodium chloricle/day, which 
suggests a moclerate average cliernry sait intake. 
Therc ·was no significant carry-over effcct, suggesting 
that the effect of each meclication clic! not depencl on 
the sequence (HCT-LIS or LIS-HCT) along vvhich 
the medications were given. The global ANOVA results 
were significant for systolic and cliastolic, for daytime as 
well as for night-time ABP (F tests, P < 0.0001). Both 
LIS and HCT significantly reducecl daytime (P < 
0.001, for systolic and diastolic) and night-time (P < 
0.005, for systolic and diastolic) ambulatory blond 
pressure (Fig. 2). Overall, LIS inclucccl a largcr daytime 
ABP rcsponse than HCT [systolic: 16.0, 95% confi-
dence interval (CI) 12.5-19.4 and 8.4 (5.0-11.9), re-
spectivcly; and diastolic: 11.5 (9.1-13.9) and 4.8 (2.3-
7.2), respectivcly] (Fig. 2). Results were similar for the 
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night-time response. In univariate linear regression 
analyses, older participants responded better to HCT 
than younger ones (P = 0.03) and the opposite trend, 
although not significant, was seen for LIS (P = 0.58). 
The significance of this effect clisappeared whcn con-
trolling for gender, Bîvll and urinary sodium excretion 
in the multivariate regression analysis. 
t-,;fen showed a greater systolic/cfüistolic ABP rcsponse 
to LIS than women, and women a greater response to 
HCT than men (Fig. 3). This was truc for the daytime 
[men, LIS: 18.8 (15.0-22.5)/14.6 (12.0-17.l), HCT: 4.9 
(1.2-8.6)/3.6 (1.0-6.2) and women, LIS: 12.4 (8.7-
16.2)/7.7 (5.1-10.2), HCT: 12.9 (9.2-16.6)/6.3 (3.7-
8.8)] and for the night-time [men, LIS: 18.7 (14.2-
22.1)/15.4 (12.4-18.5), HCT: 5.0 (0.6-9.4)/2.7 (-(0.4)-
5.7) and women, LIS: 3.5 ((-UJ)-7.9)/2.3 ((-0.8)-5.4), 
HCT: 11.5(7.1-16.0)/5.7(2.6-8.8)] responses. Men re-
spondecl better to LIS than to HCT (P < 0.001, for 
systolic and cliastolic claytime ABP), whcreas the re-
sponse to both antihypertensive drugs was comparable 
in women (P > 0.4, for systolic and cliastolic daytime 
ABP) (Fig. 3). The same patterns wcre observed for 
night-time SBP and DBP. The age-acljusted sysrolic/ 
cliastolic ABP responscs (mmHg) to HCT were 4.9/3.6 
cluring daytime and 5.0/2. 7 during night-time for men 
and 14.5/7.4 and 11.4/6.0, respectively, for women. The 
age-adjustecl systolic/diastolic ABP responses (in 
mm Hg) to LIS were 18.8/14.6 du ring claytime and 18. 7 / 
15.4 cluring night-time for men, and 12.7/7.0 and 4.0/ 
1.7, respectively, for women. 
The overall average compliance was similar for both 
meclications (85.5 ± 3.4% under HCT versus 90.2 ± 
2.7% uncler LIS, P = 0.23). The compliance die! not 
differ between men and women under LIS (men: 
90.7 ± 2.4% and women: 89.5 ± 5.2%; P = 0.83). Men 
were slightly, although not significantly, Jess compliant 
than women uncler HCT (80.7 ± 6.0 versus 90.7 ± 
2.4%, respectively; P = 0.07). Similar gencler cliffer-
ences rcgarcling the response to both clrugs were 
observed when conclucting a separatc analysis for the 
subgroup of participants who receivecl a MEMS device 
to monitor thcir compliance and those with a good 
compliance. Sevcnteen men and 16 women vverc 
monitorecl with a MEMS. Among participants with a 
compliance > 90%, the mean systolic/diastolic ABP 
responsc (in mmHg) to HCT was 5.5/4.4 (daytime) and 
7.2/5.0 (night-time) for men, whereas it was 12.9/5.5 
(daytime) and 12.6/7.4 (night-time) for womcn. Among 
those with a compliance > 90%, the mean systolic/ 
diastolic ABP response (in mmHg) to LIS was 18.9/13.3 
(daytime) and 19.8/13.8 (night-time) for men, whereas 
it was 11.5/7.8 (daytime) and 6.2/3.4 (night-time) for 
women. 
Linear regression analyses inclicated that gencler was an 
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Table 1 Participants' characteristics by gender 
Men (n = 29) Women (N = 23) 
Parameters Mean (95% Cl) Mean (95%CI) Pvalue 
Age (years) 46 (43-50) 52 (48-56) 0.04 
BMI (kg/m 2) 25.9 (24.7-27.1) 26.7 (24.8-28.6) 0.47 
Plasma 
Na (mmol/1) 140 (139-141) 140 (138-141) 0.98 
K (mmol/I) 3.9 (3.8-4.0) 3.5 {3.4-3.6) <0.0001 
Fasting blood glucose (mmol/I) 5.1 (4.5-5.7) 4.2 (3.8-4.6) 0.02 
Cholesterol (mmol/I) 5.6 (5.2-6.1) 5.7 (5.2-6.2) 0.95 
HDL-cholesterol (mmol/I) 1.33 (1.17-1.49) 1.35 (1.21-1.49) 0.83 
Creatinine (µmol/I) 79 (71-88) 75 (70-80) 0.40 
Urine 
Na (mmol/24 h) 99 (78-121) 108 (80-135) 0.61 
K (mmol/24 h) 49 (40-58) 41 (35-48) 0.21 
Baseline off·treatment ambulatory blood pressures (rnmHg) 
Daytime systolic 142 (139-145) 144 (140-148) 0.52 
Daytirne diastolic 97 (95-1 OO) 92 (89-95) 0.01 
Daytime MAP 112 (110-114) 111 (107-112) 0.13 
Night·time systolic 126 (122-130) 129 (123-135) 0.42 
Night·time diastolic 87 (84-90) 82 (78-86) 0.05 
Night·tirne MAP 100 (97-103) 98 (93-102) 0.35 
24-h systolic 138 (135-141) 139 (135-144) 0.62 
24-h diastolic 94 (92-97) 89 (86-92) 0.01 
24-h MAP 109 (106-111) 106 (103-109) 0.14 
BMI, body mass index; HDL, high·density lipoprotein; MAP, rnean arterial blood pressure; Cl, confidence interval. 
independent preclictor of the claytime ABP response to 
HCT and to LIS (Table 2). Results for night-time were 
similar. \Vhen analysing systolic and diastolic blood 
pressure separately, gender was a better predictor of 
systolic than of diastolic ABP response to therapy. 
Again, similar patterns were found for daytime and 
night-time ABP responses. None of the interaction 
terms were significant in the multiple linear regression 
analyses on claytime ABP. In partieular, neither age nor 
group (i.e. I-ICT-LIS sequence versus LIS-HCT 
sequence) significantly interactecl with gencler in the 
relationship between daytime IvlAP response and the 
selectecl variables with either treatment. 
Discussion 
Taken together, the results of the present crossover 
study show that both the ACE inhibitor and the 
diuretic significantly reduce daytime and night-time 
mean ambulatory bloocl pressure in hypertensive pa-
tients of African descent. However, the decrease in 
ambulatory blood pressure was greater with the ACE 
inhibitor than with the diuretie. :rvloreover, differential 
effects were observed in men and women: men 
responded better to the ACE inhibitor than to the 
diuretie, whereas women responded similarly to both 
classes. 
The first original observation of this study is the better 
blood pressure response to the ACE inhibitor than to 
the diuretic in a group of African hypertensive patients. 
Indeed, although our observation is consistent with two 
erossover studies of the major classes of antihyperten-
sive drugs performecl recently in Caucasian populations 
[11, 19], it is commonly acceptecl that in black hyper-
tensive patients, diuretics and ealcium-channel blockers 
are more effective antihypertensive agents than block-
ers of the renin-angiotensin system, owing to the 
lower-renin and more sait-sensitive hypertension of 
black hypertensives. In this respect, several studies 
have reported a poor response to ACE inhibition in 
Africans [20-25], in African-Americans [3,26-28] and in 
other black patients with uncomplicated essential 
hypertension [29]. Yet other investigators have obtained 
a significant blood pressure rccluction with the adminis-
tration of an ACE inhibitor in African-Americans as 
well as in black non-Americans [30-37]. 
Severa! factors couic! account for the variability of the 
blood pressure response to ACE inhibition in black 
populations. One of them could be the close of the 
ACE inhibitor. Indced, \Veir et al. [9,38] have sug-
gestecl that higher doses of ACE inhibitors may actually 
overcome the racial differences in responsiveness. The 
second important factor is the sodium intake. A reduc-
tion in sait intake has been shown repeatedly to 
enhance the efficacy of antihypertensive drugs, and 
particularly that of ACE inhibitors, whatever the race of 
the patient [9,39,40]. Thus, African-Ameriean hyper-
tensive patients do respond to the blockacle of the 
renin-angiotensin system when sait depletion is in-
duced either by the administration of a diurctie [3] or 
by the administration of a low-salt diet [9]. Unfortu-
nately, most trials investigating the antihypertensive 
efficacy of ACE inhibitors in individuals of African 
clescent provide no information on sodium intake. It is 
therefore impossible to distinguish a resistanee to the 
Copyright© Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
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ACE inhibitor due to an elevated dietary sait intake, 
which offsets the effect of ACE inhibition, \Vith a truc 
resistance to ACE inhibition. In the present study, 
sodium intake was evaluated according to the average 
24-h urinary sodium excretion before starting the anti-
hypertensive treatment. To our surprise, even in the 
absence of specific recommendation, it indicated that 
our patients had a moderate dietary sait intake of 
approximately 6 g of salt/day, which corresponds to the 
current guiclelines [41]. Hence, the good bloocl pressure 
response to ACE inhibition observed in our black 
patients may be explained by the rather low sait intake. 
It is also interesting to note that several crossover 
studies have actually found ACE inhibitors to provide a 
greater blood pressure recluction than diuretics in 
Caucasian hypertensive patients [11,42], whereas large 
prospective trials generally found either little or no 
clifference between the average blood pressure re-
sponse to ACE inhibitors and diuretics [43,44]. The 
ALLHAT trial has even suggested that cliuretics can 
decrease BP more than ACE inhibitors in a population 
including a large subgroup of African-Americans [45]. 
The study design may thus represent another factor 
leading to discrepant results. Large clinical trials are 
generally conducted using a parnllel design according to 
which different patient groups rcceived the different 
drugs under investigation. This study design is cer-
tainly convenient for large clinicat trials but it may not 
be the most adequate to investigate the therapeutic 
efficacy of varions antihypertensive strategies. Indeed, 
the mean decrease in blood pressure obtained in a 
group of hypertensive patients receiving a given ther-
apy may be Jess representative, and of little use for the 
practising physicians. In contrast, studies using a cross-
over design, in which each patient receives the differ-
ent drug classes, more closely imitate the strategy usecl 
in clinical practice and provide information on the true 
individual responsiveness. Therefore, studies with a 
crossover design may produce results that may be more 
useful than those obtainecl from parallel-study designs 
[46]. 
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Daytime ambulatory blood pressure (SBP, systolic blood pressure; 
DBP, diastolic blood pressure) response to hydrochlorothiazide (HCT) 
and lisinopril (LIS) by gender. ***: P < 0.001 for the difference in 
response between HCT and LIS. tt: P < 0.01, ttt: P < 0.001 for the 
difference in response between men and women, respectively. The 
error bars represent 95% confidence intervals corrected for multiple 
testing. 
The second observation of our study is that gender was 
the main predictor of the response to treatment, even 
after controlling for possible confounding factors such 
as age and drug sequence allocation. To our know-
Iedge, only one study, performed in obese hypertensive 
patients, has rcported similar gender differences in the 
ambulatory bloocl pressure response to LIS and HCT 
[26]. Severa! previous crossover studies have compared 
the antihypertensive effi.cacy of a diuretic with that of 
an ACE inhibitor, but these studies were either not 
large enough to stratify their results by gender 
[10,19,47,48], or clid not provide results by gender 
[11,49]. Similarly, most large trials have not shown 
signifi.cant blood pressure differences between men and 
women regarding blood pressure response. But again, as 
discussed prcviously, thesc trials were conclucted using 
a parallel design which considers only the average office 
blood pressure response to treatment and not the 
responsiveness by gender. 
An adclitional strength of our study is the electronic 
monitoring of drug aclherence for a subgroup of partici-
pants. Drug adherence is an important paramcter which 
is not always taken into account in clinical studies, but 
which may affect the interpr~tation of the clinical 
results. Since a low adherence to drug therapy had 
been measmed previously in another study conducted 
in the Seychelles [18], we thought that the electronic 
monitoring of clrug aclherence woulcl be of importance 
in the present study. The use of electronic monitors 
has enabled us to analyse the antihypertensive effi.cacy 
of the ACE inhibitor and of the diuretic, as well as the 
gender effect, according to the percentage of clrugs 
actually taken. Interestingly, the antihypcrtensive ef-
fect of both clrugs was of similar magnitude in patients 
with compliance to drug therapy greater than 90%, and 
the clifferences in achieved bloocl pressure between 
ACE inhibitors and diuretics could be confirmed. i\fore-
over, because we couic! observe similar gender differ-
ences in bloocl pressure responses to both clrugs among 
participants with a compliance greater than 90%, we are 
confident that the differential blond pressure responses 
to treatment between men and women are nor solely 
due to differences in compliance. However, some 
slightly lower response of HCT in men due to lower 
compliance to HCT cannot be excluded as men were, 
on average, slightly less compliant under the cliuretic 
than uncler the ACE inhibitor. Whether this is due to 
the occurrence of diuretic-induced side-effects, such as 
sexual dysfonction, can not be ascertainecl from our 
study. 
Perspective 
The results of the present study demonstrate that 
hypertensive individuals of East African descent with a 
moderate sait intake have a better ambulatory blood 
pressure response to 20 mg lisinopril than 25 mg hyclro-
Table 2 Univariate and multivariate relationship between mean daytime ambulatory blood pressure and selected factors in persons under 
either hydrochlorothiazide or lisinopril 
Hydrochlorothiazide (n = 52) Lisinopril (n = 52) 
Selected variables Coefficient 950/oCI Pvalue Coefficient 950/oCI Pvalue 
Univariate 
Gender (m:O, 1:1) 4.44 (0.68-8.20) 0.02 -6.71 [(-10.60)-(-2.82)] <0.001 
Age (by 1 0 years) 2.11 (0.20-4.01) 0.03 -0.61 [(-2.78)-1.56] 0.58 
BMI (kg/m2) 0.23 [(-0.29)-0, 76] 0.38 -0.28 [(-0.85)-0.29] 0.33 
Urinary Na (by 1 0 mmol/24 h) 0,02 [(-0.32)-0.37] 0.89 0.04 [(-0.34)-0.42] 0.83 
Multivariate 
Gender (m:O, 1:1) 3.76 [(-0.17)-7.70] 0.06 -6.90 [(-11.17)-(-2,64)] 0.002 
Age (by 1 0 years) 0.16 [(-0.04)-0.35] 0.11 0.04 ((-0.17)-0.25] 0.70 
BMI (kg/m2) 0.17 [(-0.33)-0.68] 0.49 -0.20 [(-0.74)-0.34] 0.46 
Urinary Na (by 1 0 mmol/24 h) 0.01 [(-0.31 )-0.34] 0.94 0.10 [{-0.25)-0.45] 0.57 
lntercept -8.36 [{-24.77)-8.05] 18.25 (0.46-36.03) 
Cl, confidence interval: BMI, body mass index. 
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chlorothiazide. This finding challenges once again the 
frequent claim that African patients respond poorly to 
ACE inhibition and emphasizes the importance of a 
modest sait restriction to irnprove the efficacy of 
antihypertensive agents, particularly ACE inhibitors. 
i'vioreover, our results show a substantial gender-specific 
difference in the ambulatory bloocl pressure response to 
antihypertensive treatments, which may suggest that 
black men and women could benefit differentially from 
antihypertensive meclications. 
References 
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, lzzo JL, 
et al. The seventh report of the Joint National Committee on prevention, 
detection and treatment of high blood pressure: the JNC 7 report. JAMA 
2003; 289:2560-2572. 
2 Chalmers J, WHO·ISH Hypertension Guidelines Committee. 1999 World 
Health Organization-lnternational Society of Hypertension Guidelines for 
the Management of Hypertension. J Hypertens 1999; 17:151-185. 
3 Veterans Administration Co·operative Study Group on Antihypertensive 
Agents. Racial differences in response to low·dose captopril are aboi· 
ished by the addition of hydrochlorothiazide. Br J Clin Pharmacol 1982; 
14:97S-101 S. 
4 Ramsay L, Williams B, Johnston G, MacGregor G, Poston L, Potter J, 
et al. Guidelines for management of hypertension: report of the third 
working party of the British Hypertension Society. J Hum Hypertens 
1999; 13:569-592. 
5 Thind GS. Demography predicts blood pressure response Io once·daily 
enalapril montherapy of mild to moderate essential hypertensive patients. 
Am J Hypertens 1988; 1 :227S-229S. 
6 Skoularigis J, Eitzman L, Davis J, Strugo V, Sareli P. Nifedipine versus 
captopril in the management of moderate hypertension in black patients, 
Am J Hypertens 1994; 7:440-447. 
7 Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond 
E, et al. Efficacy of different drug classes used to initiale antihypertensive 
treatment in black subjects: results of a randomized trial in Johannesburg, 
South Africa. Arch Infern Med 2001; 161 :965-971. 
8 Radevski IV, Valtchanova ZP, Candy GP, Hlatswayo MN, Sareli P. 
Antihypertensive effect of low·dose hydrochlorothiazide alone or in 
combination with quinapril in black patients with mild to moderate hyper· 
tension. J Clin Pharmacol 2000; 40:713-721. 
9 Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JO, 
Gunter PA, et al. Influence of race and dietary sait on the antihypertensive 
efficacy of an angiotensin·converting enzyme inhibitor or a calcium 
channel antagonist in sait-sensitive hypertensives. Hypertension 1998; 
31:1088-1096. 
1 0 Bidiville J, Nussberger J, Waeber G, Perchet M, Waeber B, Brunner HR. 
lndividual responses to converting enzyme inhibitors and calcium antago· 
nists. Hypertension 1988; 11 :166-173. 
11 Dickerson JEC, Hingorani AH, Ashby MJ, Palmer CR, Brown MJ. 
Optimisation of antihypertensive treatment by crossover rotation of four 
major classes. Lancet 1999; 353:2008-2013. 
12 Waeber B, Burnier M, Nussberger J, Brunner HR. Trials using a crossover 
design and ambulatory blood pressure recordings to determine the 
efficacy of antihypertensive agents in individual patients. J Hypertens 
1990; 8(suppl):S37-S41. 
13 Hansson L, Hedner T, Lund·Johansen P, Kjeldsen SE, Lindholm LH, 
Syvertsen JO, et al. Randomised trial of affects of calcium antagonists 
compared with diuretics and beta·blockers on cardiovascular morbidity 
and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. 
Lancet 2000; 356:359-365. 
14 Bovet P, Shamlaye C, Kitua A, Riesen WF, Paccaud F, Darioli R. High 
prevalence of cardiovascular risk factors in the Seychelles (lndian Ocean). 
Arterioscler Thromb 1991; 11 :1 730-1 736, 
15 Bovet P, Perret F, Shamlaye C, Drozd R, Paccaud F. The Seychelles 
Heart Study Il: methods and basic findings. Seychelles Med Dent J 
1997; 5:8-24, 
1 6 Waeber B, Brunner HR, Metry J-M. Compliance with antihypertensive 
treatment: implications for practice. Blood Press 1997; 6:326-331. 
1 7 Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D, et al. 
Assessing medication adherence by pill count and electronic monitoring 
inthe African American Study of Kidney Disease and Hypertension 
(AASK) Pilot Study. JAMA 1996; 9:719-725. 
18 Bovet P, Burnier M, Madeleine G, Waeber B, Paccaud F. Monitoring one· 
Gender and antihypertensive response Falconnet et al. 1219 
year compliance to antihypertension medication in the Seychelles. Bull 
WHO 2002; 80:33-39. 
19 Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS·Y, Brown MJ. 
Double·blind placebo·controlled crossover comparison of five classes of 
antihypertensive drugs. J Hypertens 2002; 20:771-777. 
20 Goodman C, Rosendorff C, Coull A Comparison of the antihypertensive 
effect of enalapril and propranolol in black South Africans. S Air Med J 
1985; 67:672-676. 
21 Radevski 1, Skudicky D, Candy G, Sathekge S, Strugo V, Sareli P. 
Antihypertensive monotherapy with nisoldipine CC is superior to enalapril 
in Black patients with severe hypertension. /,lm J Hypertens 1999; 
12:194-203, 
22 Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond 
E, et al. Efficacy of different drug classes used to initiale antihypertensive 
treatment in black subjects: results of a randomized trial in Johannesburg, 
South Africa. Arch Infern Med 2001; 161 :965-971. 
23 Skoularigis J, Eitzman L, Davis J, Strugo V, Sareli P. Nifedipine versus 
captopril in the management of moderate hypertension in black patients. 
Am J Hypertens 1994; 7:440-447. 
24 Hable B. The efficacy of hydrochlorothiazide, timolol and enalapril in 
Ethiopians with essential hypertension. Ethiop Med J 1992; 30: 
163-167. 
25 Alayi AA, Oyewo EA, Ladipo GO, Akinsola A Enalapril and hydrochlor· 
othiazide in hypertensive Africans. Eur J Clin Pharmacol 1989; 36: 
229-234. 
26 Weir MR, Reisen E, Falkner B, Hutchinson HG, Sha L, Tuck ML 
Nocturnal reduction of blood pressure and the antihypertensive response 
to a diuretic or angiotensin converting enzyme inhibitor in obese hyper-
tensive patients. TROPHY Study Group. Am J Hypertens 1998; 
11 :914-920, 
27 Thind GS. Demography predicts blood pressure response to once·daily 
enalapril monotherapy of mild to moderate essential hypertensive patients. 
Am J Hypertens 1988; 1 :227S-229S. 
28 Chrysant SG, Brown RD, Kem OC, Brown JL. Antihypertensive and 
metabolitc effects of a new converting enzyme inhibitor, enalapril. Clin 
Pharmacol Ther 1983; 33:741 -746. 
29 Moser M, Lunn J. Responses to captopril and hydrochlorothiazide in black 
patients with hypertension. Clin Pharmacol Ther 1982; 32:307-312. 
30 Weir MR, Saunders E. Renin status does not predict the anti·hyper· 
tensive response to angiotensin·converting enzyme inhibition in African· 
Americans. J Hum Hypertens 1998; 12:189-194. 
31 Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A 
comparison of the efficacy and safety of a rJ·blocker, a calcium channel 
blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch 
lntem Med 1990; 150:1707-1713. 
32 Schnaper HW, Stein G, Schoenberger JA, Lean AS, Tuck ML, Taylor AA, 
et al. Comparison of enalapril and thiazide diuretics in the elderly hyper· 
tensive patient. Gerontology 1987; 33:24-35. 
33 Cummings DM, Arnadio P, Taylor EJ, Balaban DJ, Rocci ML, Abrams WB, 
et al. The antihypertensive response to lisinopril: the effect of age in a 
predominantly black population. J Clin Pharmacol 1989; 29:25-32. 
34 Middlemost SJ, Tager R, Davis J, Sareli P. Effectiveness of enalapril in 
combination with low-dose hydrochlorothiazide versus enalapril alone for 
mild to moderate systemic hypertension in black patients. Am J Cardial 
1994; 73:1092-1097, 
35 Norton GR, Woodiwiss AJ, Hartford C, Trifunovic B, Middlemost SJ, Lee 
A, et al. Sustained antihypertensive actions of a dual angiotensin· 
converting enzyme neutral endopeptidase inhibitor, sampatrilat, in Black 
hypertensive subjects. Am J Hypertens 1999; 12:563-571. 
36 Weir MR, Kong BW, Jenkins P, Lavin PT. Comparison of the efficacy and 
tolerability of lisinopril and sustained-release verapamil in black patients 
with hypertension. Clin Ther 1991; 13:409-416. 
37 Weir MR, Lavin PT. Comparison of the efficacy and tolerability of Prinivil 
and Procardia XL in black and white hypertensive patients. Clin Ther 
1992; 14:730-739, 
38 Weir MR, Gray JM, Saunders E. Differing mechanisms of action of 
angiotensin·converting enzyme inhibition in black and white hypertensive 
patients. The Trandolapril Multicenter Study Group. Hypertension 1995; 
26:124-130. 
39 Chrysant SG, Weder AB, McCarron DA, Canossa-Terris M, Cohen JO, 
Gunter PA, et al. Effects of isradipine or enalapril on blood pressure in 
salt·sensitive hypertensives during low and high dietary sait intake. MIST 
Il Trial lnvestigators. Am J Hypertens 2000; 13:1180-1188. 
40 Kimura G, Degushi R, Kojima S, Ashida T, Yoshimi H, Abe H. Antihyper· 
tensive drugs and sodium restriction. Analysis of their interaction based 
on pressure-natriuresis relationship. Am J Hypertens 1988; 1: 
372-379. 
41 Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, 
Copyright© Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
1220 Journal of Hypertension 2004, Vol 22 No 6 
et al. Management of high blood pressure in African Americans. Arch 
Infern Med 2003; 163:525-541. 
42 Deary AJ, Schumann AL, Murfet H, Haydock SF, Fao RS-Y, Brown MJ. 
Double-blind placebo-controlled crossover comparison of five classes of 
antihypertensive drugs. J Hypertens 2002; 20:771 -777. 
43 Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman 
MH, et al. Health outcomes associated with various antihypertensive 
therapies used as first-line agents. JAMA 2003; 289:2534-2544. 
44 Wing LMH, Reid CM, Ryan P, Beilin U, Brown MA, Jennings GLR, et al. 
A comparison of outcomes with angiotensin-converting-enzyme inhibitors 
and diuretics for hypertension in the elderly. N Engl J Med 2003; 
348:583-592. 
45 The ALLHAT officers and coordinators for the ALLHA T Collaborative 
Research Group. Major outcomes in high-risk hypertensive patients 
randomized to angiotensin-converting enzyme inhibitor or calcium channel 
blocker versus diuretic. The Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 
2981 -2997. 
46 Brunner HR, Ménard J, Waeber B, Burnier M, Biollaz J, Nussberger J, 
et al. Treating the individual hypertensive patient: considerations on dose, 
sequential monotherapy and drug combinations. J Hypertens 1990; 8: 
3-11. 
4 7 Niutta E, Cusi D, Colombo R, Pellizzoni M, Cesana B, Barlassina C, et al. 
Predicting individual variations in antihypertensive therapy: the raie of 
sodium transport systems and renin. J Hypertens 1990; 8:S53-S58. 
48 Ménard J, Serrurier D, Bautier P, Plouin P-F, Corvol P. Crossover design 
to test antihypertensive drugs with self-recorded blood pressure. Hyper-
tension 1988; 11 :153-159. 
49 Attwood S, Bird R, Burch K, Casadei B, Goals A, Conway J, et al. 
Within-patient correlation between the antihypertensive effects of ateno-
lol, lisinopril and nifedipine. J Hypertens 1994; 12:1053-1060. 
Copyright© Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
